Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | IDH1 | O75874 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420908 | 0.85 | CYP4F2 (0.68) | LOXL2CYP19A1CYP4A11CYP4F2IDH1 | |
| SCHEMBL12176925 | 0.84 | LOXL2 (0.65) | LOXL2CYP4A11CYP4F2MAOAIDH1 | |
| SCHEMBL1928912 | 0.82 | TSHR (0.67) | LOXL2CYP4A11CYP4F2IDH1TP53 | |
| SCHEMBL70185 | 0.82 | CYP4A11 (0.75) | LOXL2CYP4A11CYP4F2IDH1TP53 | |
| SCHEMBL70173 | 0.79 | CYP4F2 (0.83) | LOXL2CYP4A11CYP4F2ALDH1A1HPGD | |
| SCHEMBL28069162 | 0.78 | TP53 (0.56) | LOXL2CYP19A1CYP4A11CYP4F2MAOA | |
| SCHEMBL3482674 | 0.78 | CYP19A1 (0.91) | CYP19A1MAOAMAOBCYP3A4MAPT | |
| SCHEMBL1926802 | 0.78 | CYP4F2 (0.76) | LOXL2CYP4A11CYP4F2ALDH1A1HPGD | |
| SCHEMBL17429664 | 0.78 | CYP4A11 (0.60) | LOXL2CYP4A11CYP4F2IDH1TP53 | |
| SCHEMBL12176878 | 0.78 | CYP4A11 (0.70) | LOXL2CYP4A11CYP4F2MAOAIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107337621-A | Dicarboxylic acid compound | 第三共株式会社 | 2017-11-10 | — | — | CN | disclosed |
| CN-107311895-A | Dicarboxylic acid compound | 第三共株式会社 | 2017-11-03 | — | — | CN | disclosed |
| EP-2990400-B1 | DICARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9670173-B2 | Dicarboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9617232-B2 | Dicarboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20170015641-A1 | DICARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2990400-A1 | DICARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20160046568-A1 | DICARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| CN-105121405-A | Dicarboxylic acid compound | DAIICHI SANKYO CO LTD | 2015-12-02 | — | — | CN | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2772490-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1761486-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000288-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | SLC34A2, SLC10A2, ALPI | LOXL2 3364/4885CYP19A1 4367/4885CYP4A11 2733/4885 |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | LOXL2 2027/4885CYP19A1 351/4885CYP4A11 31/4885 |
| US-20170015641-A1 | DICARBOXYLIC ACID COMPOUND | CA2, HCAR2, SLC5A2 | LOXL2 1456/4885CYP19A1 2402/4885CYP4A11 2023/4885 |
| US-20160046568-A1 | DICARBOXYLIC ACID COMPOUND | CA2, HCAR2, SLC5A2 | LOXL2 1456/4885CYP19A1 2402/4885CYP4A11 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.